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Résumé en
anglais
The therapeutic potential of cannabinoids has been truly constrained heretofore due to
their strong psychoactive effects and their high lipophilicity. In this context, precisely
due to the lack of psychoactive properties, cannabidiol (CBD), the second major
component of Cannabis sativa, arises as the phytocannabinoid with the most
auspicious therapeutic potential. Hence, the incorporation of CBD in lipid
nanocapsules (LNCs) will contribute to overcome the dosing problems associated with
cannabinoids. Herein, we have prepared LNCs decorated and loaded with CBD for
glioma therapy and screened in vitro their critical parameters. On the one hand, we
have encapsulated CBD into the oily core of LNCs to test their in vitro efficacy as
extended-release carriers against the human glioblastoma cell line U373MG. The in
vitro antitumor effect was highly dependent on the size of LNCs due to its pivotal role
in the extent of CBD release. Effectively, a comparison between two differently-sized
LNCs (namely, 20-nm and 50-nm sized carriers) showed that the smaller LNCs reduced
by 3.0-fold the IC value of their 50-nm sized counterparts. On the other hand, to
explore the potential of this phytocannabinoid to target any of the cannabinoid
receptors overexpressed in glioma cells, we decorated the LNCs with CBD. This
functionalization strategy enhanced the in vitro glioma targeting by 3.4-fold in
comparison with their equally-sized undecorated counterparts. Lastly, the combination
of CBD-loading with CBD-functionalization further reduced the IC values. Hence, the
potential of these two strategies of CBD incorporation into LNCs deserves subsequent
in vivo evaluation.
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